A nationwide cohort study in JAMA Internal Medicine of 80,178 patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes treated with oral antidiabetic medication found that sodium-glucose cotransporter 2 inhibitors were associated with a higher probability of MASLD regression and lower adverse liver-related outcomes compared with other antidiabetic drugs. “SGLT2 inhibitors were distinguished by their association with fatty liver improvement, surpassing other [oral antidiabetic drugs] known for their potential benefits in MASLD," said Dr. Won Kim, a study author.
Full Story: Healio (free registration) (3/13)